GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » PS Ratio

AUPH (Aurinia Pharmaceuticals) PS Ratio : 6.63 (As of Dec. 11, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aurinia Pharmaceuticals's share price is $10.11. Aurinia Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.53. Hence, Aurinia Pharmaceuticals's PS Ratio for today is 6.63.

The historical rank and industry rank for Aurinia Pharmaceuticals's PS Ratio or its related term are showing as below:

AUPH' s PS Ratio Range Over the Past 10 Years
Min: 3.68   Med: 380.63   Max: 10710
Current: 6.61

During the past 13 years, Aurinia Pharmaceuticals's highest PS Ratio was 10710.00. The lowest was 3.68. And the median was 380.63.

AUPH's PS Ratio is ranked better than
56.5% of 1016 companies
in the Biotechnology industry
Industry Median: 8.76 vs AUPH: 6.61

Aurinia Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2024 was $0.47. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.53.

Warning Sign:

Aurinia Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Aurinia Pharmaceuticals was 36.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 42.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 257.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 55.70% per year.

During the past 13 years, Aurinia Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 580.20% per year. The lowest was -84.10% per year. And the median was -10.60% per year.

Back to Basics: PS Ratio


Aurinia Pharmaceuticals PS Ratio Historical Data

The historical data trend for Aurinia Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals PS Ratio Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,753.33 32.70 64.79 4.58 7.34

Aurinia Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.97 7.34 3.75 3.96 4.81

Competitive Comparison of Aurinia Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Aurinia Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's PS Ratio falls into.



Aurinia Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Aurinia Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=10.11/1.525
=6.63

Aurinia Pharmaceuticals's Share Price of today is $10.11.
Aurinia Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.53.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Aurinia Pharmaceuticals  (NAS:AUPH) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Aurinia Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals Business Description

Traded in Other Exchanges
Address
14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott Michael Habig officer: Chief Commercial Officer #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
R. Hector Mackay-dunn director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w. director #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Daniel Billen director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Jill Leversage director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Matthew Maxwell Donley officer: Ex VP, Intern'l Operations 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Stephen P. Robertson officer: EVP, General Counsel #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Joseph M Miller officer: Chief Financial Officer C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Peter Greenleaf director, officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Volker Knappertz officer: EVP, Research and Development SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster director C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037

Aurinia Pharmaceuticals Headlines

From GuruFocus